CliffBio
small molecule

TAVIST

CLEMASTINE FUMARATE

Loss of exclusivity—loss of exclusivity
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameTAVIST
Active ingredientCLEMASTINE FUMARATE
StrengthEQ 0.5MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formSYRUP
RouteORAL
ModalitySmall molecule
FDA approvalJune 1985
Marketing statusDISCN

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.